Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: An Israeli population-based case-control study

被引:69
作者
Rutter, JL
Wacholder, S
Chetrit, A
Lubin, F
Menczer, J
Ebbers, S
Tucker, MA
Struewing, JP
Hartge, P
机构
[1] NCI, Div Canc Epidemiol & Genet, Epidemiol & Biostat Program, NIH, Bethesda, MD 20892 USA
[2] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel
[3] Edith Wolfson Med Ctr, Holon, Israel
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2003年 / 95卷 / 14期
关键词
D O I
10.1093/jnci/95.14.1072
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In the general population, the risk of developing ovarian cancer is reduced in women who have undergone tubal ligation, hysterectomy, or oophorectomy, although peritoneal cancer can arise after bilateral oophorectomy. In studies from genetic screening clinics, women with mutations in the breast and ovarian susceptibility genes BRCA1 and BRCA2 have been found to have a low risk of peritoneal carcinoma in the first years after bilateral oophorectomy. We assessed the level and persistence of reduction of ovarian (including peritoneal) cancer risk after gynecologic surgeries for women who carry BRCA1/2 mutations but were not selected from high-risk clinics. Methods: We identified 1124 Israeli women with incident ovarian cancer or primary peritoneal cancer and tested 847 of them for the three Ashkenazi founder mutations. We compared gynecologic surgery history among all case patients, BRCA1 (n = 187) and BRCA2 (n = 64) carrier case patients, and the non-carrier case patients (n = 598) with that in control subjects drawn from a population registry (n = 2396). We estimated ovarian cancer risk (odds ratios [ORs] with 95% confidence intervals [CIs]) after gynecologic surgery in mutation carriers and non-carriers with logistic regression models. Results: Eight women with primary peritoneal cancer and 128 control subjects reported a previous bilateral oophorectomy (OR = 0.12, 95% CI = 0.06 to 0.24). Other gynecologic surgeries were associated with a 30%-50% reduced risk of ovarian cancer, depending on the type of surgery, with surgery to remove some ovarian tissue associated with the most risk reduction (OR = 0.34, 95% CI = 0.16 to 0.74). Reduced risks were seen in BRCA1/2 carriers and non-carriers. Age at surgery and years since surgery did not affect risk reductions. Conclusion: Both BRCA1/2 mutation carriers and non-carriers have reduced risk of ovarian or peritoneal cancer after gynecologic surgery. The magnitude of the reduction depends upon the type and extent of surgery.
引用
收藏
页码:1072 / 1078
页数:7
相关论文
共 37 条
[1]   Limitations of the case-only design for identifying gene-environment interactions [J].
Albert, PS ;
Ratnasinghe, D ;
Tangrea, J ;
Wacholder, S .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2001, 154 (08) :687-693
[2]  
AMOS CI, 1993, CANCER-AM CANCER SOC, V71, P566
[3]  
Barrett-Connor E, 1998, BMJ-BRIT MED J, V317, P457
[4]  
Brinton LA, 2000, BRIT J CANCER, V82, P1600
[5]  
CATTANACH J, 1985, LANCET, V1, P847
[6]   LONG-TERM RISK OF MENSTRUAL DISTURBANCES AFTER TUBAL-STERILIZATION [J].
DESTEFANO, F ;
PERLMAN, JA ;
PETERSON, HB ;
DIAMOND, EL .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1985, 152 (07) :835-841
[7]  
EASTON DF, 1995, AM J HUM GENET, V56, P265
[8]   Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene [J].
Gayther, SA ;
Mangion, J ;
Russell, P ;
Seal, S ;
Barfoot, R ;
Ponder, BAJ ;
Stratton, MR ;
Easton, D .
NATURE GENETICS, 1997, 15 (01) :103-105
[9]  
Green A, 1997, INT J CANCER, V71, P948
[10]   TUBAL-LIGATION, HYSTERECTOMY, AND RISK OF OVARIAN-CANCER - A PROSPECTIVE-STUDY [J].
HANKINSON, SE ;
HUNTER, DJ ;
COLDITZ, GA ;
WILLETT, WC ;
STAMPFER, MJ ;
ROSNER, B ;
HENNEKENS, CH ;
SPEIZER, FE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (23) :2813-2818